Cabozantinib, approved by the FDA for renal cell carcinoma and medullary thyroid carcinoma, targets multiple receptor tyrosine kinases, including MET, RET, AXL, TRKA, and TRKB [42,43,44]. The gene discussed is NTRK1; the disease is renal cell carcinoma.